izalontamab brengitecan   Click here for help

GtoPdb Ligand ID: 14566

Synonyms: BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
Approved drug
izalontamab brengitecan is an approved drug
Compound class: Antibody
Comment: Izalontamab brengitecan (BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) that is designed to deliver the camptothecin derived topoisomerase I inhibitor Ed-04 payload to tumour cells that express EGFR and HER3 receptor tyrosine kinases. The drug carries of eight toxin molecules per antibody (SI-B001) molecule [7,9]. Peptide sequences for the heavy and light chains of the parental antibody (obtained from the INN record) are claimed in patent US10919977, specifically for the clone named SI-1X6.4 [3].
Click here for help
Bioactivity Comments
The parental antibody izalontamab (SI-B001) binds to functional receptor dimers containing EGFR and/or HER3 and blocks downstream signalling pathways that would otherwise promote tumour proliferation and survival processes [8]. Acquired resistance to BL-B01D1 is thought to be linked to treatment-induced upregulated expression of the ABCG2 transporter [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
epidermal growth factor receptor Primary target of this compound Hs Antibody Binding ~8.5 pKd - 3
⤷ pKd ~8.5 (Kd ~3x10-9 M) [3]
erb-b2 receptor tyrosine kinase 3 Primary target of this compound Hs Antibody Binding - - - 3
⤷ [3]